Gastroesophageal Reflux Clinical Trial
Official title:
LINX Reflux Management System Clinical Study Protocol
The purpose of the study is to evaluate the safety and effectiveness of the LINX Reflux Management System in the treatment of Gastroesophageal Reflux Disease (GERD).
At present, the primary alternative for GERD patients with an incomplete symptomatic response
to proton-pump inhibitors (PPIs) is laparoscopic Nissen fundoplication. This surgical
procedure continues to be the prevalent non-medical treatment option for GERD patients,
despite several important limitations. First, it is a very traumatic procedure, requiring
portions of the stomach to be dissected and then wrapped around the tubular esophagus,
creating permanent anatomic alterations. Secondly, it can create significant side effects,
such as gas bloat syndrome, the inability to belch and the inability to vomit.
The intent of the LINX System is to allow a surgeon, using existing laparoscopic techniques
and instruments, to augment a weak LES and restore the defective barrier at the
gastroesophageal junction (GEJ). This defect of the GEJ is the source of abnormal reflux. The
LINX device is an expandable string of individual titanium beads with magnetic cores. The
device is laparoscopically placed as a ring around the lower esophageal sphincter. The
magnetic attraction of the beads augments the esophageal sphincter's ability to resist
gastric pressures that cause reflux. At rest, the LINX device encircles the sphincter with
each bead resting against an adjacent bead, to avoid compression of the tubular esophagus.
When swallowing, higher pressures are created, allowing the magnetic bond between beads to
break, and the LINX implant to expand radially. This serves to preserve swallow and other
physiologic functions, such as belching and vomiting, and avoids the side effect of
post-prandial bloating. The device can be placed with minimal dissection, preserving anatomy,
and is also removable, if necessary. This provides important benefits as it preserves the
native anatomy, unlike the Nissen procedure.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |